Neurochem Faces Obstacles To Making Supplement Out Of Drug Candidate
This article was originally published in The Tan Sheet
Executive Summary
Neurochem's plan to market a failed Alzheimer's disease drug candidate as a dietary supplement could stumble in the United States over requirements of the Dietary Supplement Health and Education Act, regulatory experts say